This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Novartis Ag, University of California. Active years: 2024.
Company Filing History:
1 out of 3,974 
1 out of 15,988 
Years Active: 2024
Title: The Innovations of Markus Schirle
Introduction
Markus Schirle is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biochemistry, particularly in the area of targeted protein degradation. His work has implications for therapeutic development and drug discovery.
Latest Patents
Markus Schirle holds a patent titled "Covalent targeting of E3 ligases." This patent discloses compositions and methods for targeting E3 ligases. It includes a targeted protein degrader that consists of a targeted protein binder and an E3 Ubiquitin ligase binder, specifically human RNF4 or human RNF114. Additionally, the patent provides a pharmaceutical composition that includes the described compound and a pharmaceutically acceptable excipient. He has 1 patent to his name.
Career Highlights
Throughout his career, Markus Schirle has worked with prestigious organizations, including the University of California and Novartis AG. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.
Collaborations
Markus has collaborated with notable colleagues such as Daniel K. Nomura and Jessica Spradlin. Their joint efforts have furthered the understanding of protein interactions and degradation mechanisms.
Conclusion
Markus Schirle's innovative work in the field of biochemistry, particularly in targeted protein degradation, showcases his contributions to science and medicine. His patent and collaborations highlight the importance of teamwork in advancing research.